CCL19 and pancreatic adenocarcinoma: Stimulation of the CCR7-expressing pancreatic adenocarcinoma-derived cell line, PANC1, with CCL19 led to enhanced expression of p-ERK, p-AKT, N-cadherin and MMP-9, markers of EMT progression, further implicating CCR7 in the metastatic progression of pancreatic adenocarcinomas [148].